News

Minaris Regenerative Medicine is proud to share current and past news and announcements from its over twenty years of experience. Please see below for our press releases and announcements.

*This page may include mention of our past company names as it reflects content distributed in the past. The former companies Hitachi Chemical Advanced Therapeutics Solutions (HCATS, fomerly PCT or PCT Cell Therapy Services), apceth Biopharma GmbH, and Hitachi Chemical Co., Ltd. have been renamed Minaris Regenerative Medicine and are part of the Resonac Group.
June 19, 2024

Business alliance with Cryoport (Japanese)

Yokohama, Japan - June 20th, 2024 - We are pleased to inform you that Minaris Regenerative Medicine Co., Ltd. and Cryoport, Inc. have entered into a business alliance. Details in Japanese for local news in Japan.    Cryoport, Inc.(本社:テネシー州、CEO Jerrell W. Shelton、以下 Cryoport)とMinaris Regenerative Medicine株式会社(本社:神奈川県横浜市、代表取締役社長 坂東 博人、以下 Minaris)は、再生医療等製品の輸送に関する業務提携契約を締結しました。  ...

June 13, 2024

Minaris Regenerative Medicine Implements Manufacturing Execution System Werum PAS-X MES

Lüneburg and Ottobrunn, Germany, June 13, 2024 – Minaris Regenerative Medicine GmbH (Minaris), a leading contract development and manufacturing organization for cell and gene therapies, has implemented a digital Manufacturing Execution System (MES), the newest version of Werum PAS-X MES by Körber, at its German site in Ottobrunn near Munich. By doing so, Minaris is converting its production ...

June 3, 2024

Business alliance with Myoridge (Japanese)

Yokohama, Japan - June 4th, 2024 - We are pleased to inform you that Minaris Regenerative Medicine Co., Ltd. and Myoridge Co., Ltd. have entered into a business alliance. Details in Japanese for local news in Japan.  株式会社マイオリッジ(本社:京都府京都市、代表取締役社長 牧田 直大、以下マイオリッジ)とMinaris Regenerative Medicine株式会社(本社:神奈川県横浜市、代表取締役社長 坂東 博人、以下 Minaris)は、培地最適化による再生医療等製品の製造プロセス開発支援に関する業務提携契約を締結しました。   ...

May 8, 2024

First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, NJ.

With the recent FDA approval of LYFGENIA™, developed by bluebird bio, Minaris Regenerative Medicine North America is now supporting a commercial cell and gene therapy (CGT) product. The first commercial drug product was manufactured in early May. This confirms the capability of Minaris Regenerative Medicine as a commercial manufacturing CDMO. Allendale, NJ, USA, Wednesday 08 May 2024 – Minaris ...

March 14, 2024

Business alliance with VectorBuilder Inc. (Japanese)

Yokohama, Japan - March 14th, 2024 - We are pleased to inform you that Minaris Regenerative Medicine Co., Ltd. and VectorBuilder Inc. have entered into a business alliance. Details in Japanese for local news in Japan.  Minaris Regenerative Medicine株式会社(本社:神奈川県横浜市、代表取締役社長 坂東 博人、以下 Minaris)は、VectorBuilder Inc.(本社:Chicago, IL 60609, USA、最高科学責任者 Bruce Lahn, Ph.D.、以下 VectorBuilder)と業務提携を結んだことをお知らせします。 ...

March 7, 2024

Hiroto Bando Appointed CEO of Minaris Regenerative Medicine GmbH (Germany)

Munich, Germany - November 28th, 2023 - Minaris Regenerative Medicine GmbH, a leading contract development and manufacturing organization (CDMO) for the cell and gene therapy industry fully owned by Resonac Group, announces the appointment of Hiroto Bando, PhD as CEO of the European operations of Minaris Regenerative Medicine (Minaris) as of November 28, 2023. Hiroto Bando assumes this new role ...

September 6, 2023

Minaris Regenerative Medicine Selects Apprentice.io’s Tempo Manufacturing Execution System to Scale Commercial Production

JERSEY CITY, N.J. - September 6th, 2023 - Apprentice.io, leading technology provider for life sciences manufactures, announced that Minaris Regenerative Medicine, a leading contract development and manufacturing organization (CDMO) focused on cell and gene therapies, has selected Apprentice’s Tempo Manufacturing Execution System (MES) to digitize its commercial manufacturing in North America and ...

May 24, 2023

Minaris Regenerative Medicine Streamlining Contract Manufacturing with Veeva Vault Quality Suite Applications

Pleasanton, CA - May 24, 2023 - Veeva Systems (NYSE: VEEV) today announced that Minaris Regenerative Medicine, a leading contract development and manufacturing organization (CDMO) focused on cell and gene therapies, selected Veeva Vault QualityDocs and Veeva Vault Training to advance its global quality operations. Minaris Regenerative Medicine will use Veeva’s unified quality applications to ...

February 16, 2023

LIfT BioSciences and Minaris Regenerative Medicine Enter into a Development and Manufacturing Partnership for N-LIfT Allogeneic Neutrophil Based Cell Therapy

LONDON, UK and MUNICH, GERMANY - February 16, 2023 - LIfT BioSciences, a pioneering pre-clinical stage company moving into first-in-human trials with an allogeneic neutrophil progenitor based cell therapy, and Minaris Regenerative Medicine GmbH, a leading global contract development and manufacturing service provider for the cell and gene therapy industry, have entered into a development and ...

All Posts